S100P is a useful marker for differentiation of ovarian mucinous tumors

The S100P protein stimulates cell proliferation and survival, thereby contributing to tumor progression. The purpose of this study was to evaluate S100P expression in the three subtypes of mucinous cystic tumors, cystadenomas, borderline tumors, and adenocarcinomas. The authors examined nuclear S100P expression in 60 mucinous ovarian tumor specimens, including 24 specimens of mucinous cystadenoma, 15 of borderline tumors, and 21 of adenocarcinomas. Immunohistochemistry revealed S100P expression followed one of three patterns: (1) Expressed in most nuclei of mucinous epithelial cells, (2) sporadic (spotted or patchy) expression, or (3) absent or rarely expressed in the nuclei of mucinous epithelial cells. Most adenomas showed the first expression pattern, and borderline tumors often showed a patchy expression pattern. Adenocarcinomas generally demonstrated absence of S100P expression. These data suggest that S100P is a useful histological marker to differentiate between benign, borderline, and malignant mucinous tumors of the ovary.

Mucinous tumor; Ovary; S100P; Immunohistochemistry.

[1] Streicher W.W., Lopez M.M., Makhatadze G.I.: “Modulation of quaternary structure of S100 proteins by calcium ions”. Biophys. Chem., 2010, 151, 181.

[2] Arumugam T., Simeone D.M., Schmidt A.M., Logsdon C.D.: “S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE)”. J. Biol. Chem., 2004, 279, 5059.

[3] Koltzscher M., Neumann C., Konig S., Gerke V.: “Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P”. Mol. Biol. Cell., 2003, 14, 2372.

[4] Filipek A., Jastrzebska B., Nowotny M., Kuznicki J.: “CacyBP/ SIP, a calcyclin and Siah-1-interacting protein, binds EFhand proteins of the S100 family”. J. Biol. Chem., 2002, 277, 28848.

[5] Whiteman H.J., Weeks M.E., Dowen S.E., Barry S., Timms J.F., Lemoine N.R., et al.: “The role of S100P in the invasion of pancreatic cancer cells is mediated through cyto- skeletal changes and regulation of cathepsin D”. Cancer Res., 2007, 67, 8633.

[6] Logsdon C.D., Simeone D.M., Binkley C., Arumugam T., Greenson J.K., Giordano T.J., et al.: “Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.” Cancer Res., 2003, 63, 2649.

[7] Bertram J., Palfner K., Hiddemann W., Kneba M.: “Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin- resistant cell lines: comparison of mRNA differential display reverse transcription- polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression”. Anticancer Drugs, 1998, 9, 311.

[8] Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al.: “Gene- expression profiles predict survival of patients with lung adenocarcinoma”. Nat. Med., 2002, 8, 816.

[9] Guerreiro Da Silva I.D., Hu Y.F., Russo I.H., Ao X., Salicioni A.M., Yang X, Russo J.: “S100P calcium-binding protein overexpres- sion is associated with immortalization of human breast epithe- lial cells in vitro and early stages of breast cancer development in vivo”. Int. J. Oncol., 2000, 16, 231.

[10] Averboukh L., Liang P., Kantoff P.W., Pardee A.B.: “Regulation of S100P expression by androgen”. Prostate, 1996, 29, 350.

[11] Surowiak P., Maciejczyk A., Materna V., Drag-Zalesinska M., Wojnar A., Pudelko M., et al.: “Unfavourable prognostic significance of S100P expression in ovarian cancers”. Histopathology, 2007, 51, 125.

[12] Aishima S., Fujita N., Mano Y., Kubo Y., Tanaka Y., Taketomi A., et al.: “Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type”. Am. J. Surg. Pathol., 2011, 35, 590.

[13] Gao J.H., He Z.J., Wang Q., Li X., Li Y.X., Liu M., et al.: “Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line”. Chin. Med. J. (Engl.), 2008, 121, 1563.

[14] Wang Q., He Z., Gao J., Hu S., Huang M., Liu M., et al.: “S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro”. Cancer Lett., 2008, 272, 277.